Huisheng Bio Completes RMB 500 Million Series A Financing with ECF Capital as Exclusive Financial Advisor

VCBeat learned that recently,Four Rings Pharmaceutical Holdings Group Co., Ltd.（"Four Rings Medicine", Stock Code: 0460) announced that its non-wholly owned subsidiary, Jilin Huisun Biopharmaceutical Co., Ltd. ("Huisun Bio"), has completed a 500 million yuan Series A financing round. This round of financing was jointly invested by China Life Healthcare Fund, Tianjin Yuanyi, Tianjin Yuanyi Jimao, and Gingko Capital.

CEC Capital served as the exclusive financial advisor to Huisen Bio in this transaction.

In order to fully expand the billion-dollar track of diabetes, Siho Med has2014Established Huisheng Bio, a biopharmaceutical company focused on diabetes and its complications. After 7 years of meticulous development and investment exceeding RMB1.5 billionYuan. Currently, Huisheng Biotechnology's scale exceeds200 people, with an internationally leading professional R&D team experienced in diabetes drug development, and has successfully developedNearly 40A rich and comprehensive product pipeline at different stages, achieving full coverage of targets in the diabetes field. The product line includes a full range of second-generation, third-generation, and fourth-generation insulin and analog product pipelines (covering basal, premixed, and rapid-acting products), as well as innovative drugs based on the latest mechanisms.SGLT-2、GLP-1、DPP-4Products such as various mechanisms of hypoglycemic drugs and complication medications.

Chairman of Four Rings Pharmaceutical Holdings Group, Fengsheng CheStated: "Huisheng Biopharma is currently the only biopharmaceutical company in China that has achieved full product coverage in the field of diabetes and its complications. The successful completion of this Series A round of financing not only reflects the recognition by various investors of Huisheng Biopharma's R&D strength and industrialization capabilities, but also their confidence and expectations in the value creation and broad market prospects of the company’s comprehensive product pipeline in the field of diabetes and its complications. The funds from this round of financing will mainly be used to meet the normal operational needs of Huisheng Biopharma, including clinical advancement of products under research, purchase of production equipment, and replenishment of working capital for operations. This round of financing was the Series A investment made by four investors. We thank them for their strong support, which enables Huisheng Biopharma to continue making efforts in the biopharmaceutical field, benefiting more patients with diabetes and its complications."

Jiang Li, Managing Director of Guoshou Equity Company"It said: 'In recent years, the prevalence of diabetes has continued to rise, becoming a major global challenge faced by individuals, families, and society. We are very fortunate to participate in the first round of financing of HuiSheng Biopharma. We highly recognize HuiSheng Biopharma's full product deployment in the field of diabetes drug research and development and complication treatment, and we are very optimistic about the company's future value. China Life Equity will continue to support HuiSheng Biopharma in growing into a biopharmaceutical leader providing comprehensive solutions for diabetes and its complications, benefiting patients worldwide.'"

Zhang Liang, Managing Director of CEC Capital"We are honored to assist Huisheng Bio in completing this transaction. Huisheng Bio, under the Four Rings Medicine group, is a rare investment target in China's diabetes field and is the only company in China that has achieved full coverage in the diabetes and complications field. We are pleased to see that our value judgment aligns highly with top-tier investors in this round. We look forward to Huisheng Bio providing the most valuable comprehensive solutions for the large number of diabetes patients worldwide."

HuiSheng Biopharma is a biopharmaceutical company under the group that focuses on the field of diabetes and its complications. After seven years of development, the company now has an international first-class R&D team of over 200 people with extensive experience in diabetes drug research and development. It currently holds a full product pipeline of nearly 40 products for diabetes and its complications, covering the entire range of second-generation, third-generation, and fourth-generation insulin and analog product pipelines (including basal, premixed, and fast-acting products), innovative drugs based on the latest mechanisms such as SGLT-2, GLP-1, DPP-4, and other hypoglycemic drugs and complication treatments of various mechanisms. HuiSheng Biopharma is currently the only biopharmaceutical company in China that achieves full product coverage in the field of diabetes and its complications, integrating R&D, production, and sales as a whole industry chain. It is committed to providing comprehensive, integrated treatment solutions for diabetes patients, serving patients, and making health simpler.

China Life Equity led the investment in this financing round of Huisen Bio, with Tianjin Yuanyi, Tianjin Yuanyi Jimao, and Ginkgo Capital as co-investors. Among them, China Life Equity, the leading investor, is a specialized private equity investment platform under China Life, adhering to the investment philosophy of "investing in the future, investing in innovation, and investing in value." It has made extensive investment layouts in the fields of life sciences, medical technology, medical services, and digital healthcare, investing in a group of leading enterprises in China's healthcare industry.

Four Rings Pharmaceutical Holdings Group Co., Ltd. ("Four Rings Pharmaceutical" or "the Company," together with its subsidiaries as "the Group") (Stock Code: 0460 HKEX) was founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010. It is an international pharmaceutical and medical aesthetics enterprise led by innovation, possessing an independently advanced R&D technology platform, a rich global product pipeline, strong product registration capabilities, a highly efficient and low-cost full-dosage production platform, and a mature and excellent sales system. Four Rings Pharmaceutical has always adhered to the overall strategic goal of "fully advancing the dual-driven strategy of medical aesthetics and biopharmaceuticals at full speed" to build a leading medical aesthetics and biopharmaceutical enterprise in China.

CEC Capital is a leading investment bank in China's new economy, focusing on three major industries globally: TMT, consumer, and healthcare. In addition to its investment banking services, CEC Capital manages both a Renminbi fund and a US Dollar fund. The company has offices in Beijing, Shanghai, Los Angeles, and San Francisco, and holds a US securities market license. The healthcare industry is one of CEC Capital’s key areas of focus where it has significant expertise and advantage. For five consecutive years, it has been the new economy investment bank with the most healthcare industry transaction records in China. Moreover, CEC Capital boasts the largest, most professional, and most comprehensively covered healthcare investment banking team in China.